-The Hindu Hearings suspended in Maharashtra, Kerala, Rajasthan A quick survey of the fallout of the Supreme Court order directing that State Information Commissions “henceforth” work on benches of two members each — one of them a ‘judicial member’ and the other an ‘expert member’ — has shown that work in some SICs hearing appeals under the Right to Information (RTI) Act has ground to a halt. Other SICs found no barrier to...

-The Hindu The Supreme Court order on the appointment of Information Commissioners has had an unsettling effect on the working of the Right to Information Act, an elegant seven-year old law that has immeasurably empowered the average citizen. What was designed as an easy-to-use legal tool for the poor and weak may now be at risk of getting tangled in a web of complexity. The Court has, inter alia, ruled that...

-The Hindu Petition says plant should be governed by principle of ‘absolute liability, polluter pays’ A fresh writ petition has been filed in the Supreme Court, contending that the Kudankulam nuclear power plant could not be commissioned without resolving the issue of Russia’s liability in case of an accident. The public interest litigation petition sought a declaration that the plant, in Tirunelveli district, would be governed by the law of the land, as...

-The Times of India India is likely to be on an unchartered territory when it implements the Supreme Court order mandating the presence of a judicial officer and an expert to hear appeals in information commissions across the country. According to an independent survey on information commissions across the world there was no precedent of retired or serving judges as members of panels hearing cases related to freedom of information. The rapid...

-The Economic Times MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco. The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at...